Prognostic impact of radiation therapy in tubular carcinoma of the breast.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
06 2021
Historique:
received: 13 10 2020
revised: 09 03 2021
accepted: 10 03 2021
pubmed: 24 3 2021
medline: 29 6 2021
entrez: 23 3 2021
Statut: ppublish

Résumé

Tubular carcinoma (TC) is an invasive breast cancer with favorable prognosis. While pathology-specific guidelines exist for TC regarding adjuvant chemotherapy and endocrine therapy, no recommendations exist regarding locoregional treatment based on tumor histology. Prognostic impact of radiotherapy for patients with TC remains unclear. The National Cancer Database was queried (2004-2015) for patients with pN0M0 TC who underwent lumpectomy. Chi-square testing compared categorized variables between those who did and did not receive radiotherapy. Kaplan-Meier analysis evaluated overall survival (OS). Cox proportional hazard analysis identified variables prognostic for OS. Patients were divided into age cohorts ≤60 years and >60 years. Propensity score matching (PSM) was utilized to create similar cohorts. 9705 patients met selection criteria; 6182 (75.1%) received radiotherapy while 2045 (24.9%) did not. After PSM, radiotherapy (HR 0.582; 95% CI 0.494-0.686) and endocrine therapy (HR 0.737; 95% CI 0.623-0.872) were favorable prognostic factors on multivariate Cox regression analysis while age > 60 years (HR 5.131; 95% CI 3.753-7.016), Black race (HR 1.445; 95% CI 1.016-2.055), and Charlson-Deyo comorbidity score > 0 (HR 1.708; 95% CI 1.403-2.079) were unfavorable prognostic factors. After PSM, 5-year OS was 91.7% for those who received radiotherapy and 84.5% for those who did not; 10-year OS was 76.1% and 64.1%, respectively (p < 0.001). This is the largest study to date on TC and the prognostic impact of adjuvant radiotherapy. Postoperative radiotherapy is a favorable prognostic factor for OS in patients with pN0M0 TC, suggesting adjuvant radiotherapy should remain standard of care in these patients.

Identifiants

pubmed: 33753158
pii: S0167-8140(21)06135-1
doi: 10.1016/j.radonc.2021.03.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

202-208

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Jessica Stauber (J)

The University of Texas Medical Branch at Galveston, Department of Radiation Oncology, Galveston, United States.

Neil Chevli (N)

The University of Texas Medical Branch at Galveston, Department of Radiation Oncology, Galveston, United States.

Waqar Haque (W)

Houston Methodist Hospital, Department of Radiation Oncology, United States.

Jay A Messer (JA)

The University of Texas Medical Branch at Galveston, Department of Radiation Oncology, Galveston, United States.

Andrew M Farach (AM)

Houston Methodist Hospital, Department of Radiation Oncology, United States.

Mary R Schwartz (MR)

Houston Methodist Hospital, Department of Pathology and Genomic Medicine, United States.

Charles E Geyer (CE)

Houston Methodist Hospital, Department of Oncology, Houston, United States.

Elizabeth Bonefas (E)

Baylor College of Medicine, Department of General Surgery, Houston, United States.

Raed Zuhour (R)

The University of Texas Medical Branch at Galveston, Department of Radiation Oncology, Galveston, United States.

Andrew Wong (A)

The University of Texas Medical Branch at Galveston, Department of Radiation Oncology, Galveston, United States.

Sandra Hatch (S)

MD Anderson Cancer Center, Department of Radiation Oncology, Houston, United States.

E Brian Butler (E)

Houston Methodist Hospital, Department of Radiation Oncology, United States.

Bin S Teh (BS)

Houston Methodist Hospital, Department of Radiation Oncology, United States. Electronic address: bteh@houstonmethodist.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH